Obsidian Therapeutics, Inc. (OBX)
| Market Cap | 1.76B |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 61.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,366 |
| Open | 30.00 |
| Previous Close | 34.00 |
| Day's Range | 23.00 - 30.30 |
| 52-Week Range | 3.02 - 49.97 |
| Beta | 2.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OBX
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that le... [Read more]
News
Obsidian Therapeutics, Inc. Common Stock trading halted, volatility trading pause
09:49 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading halted, volatility trading pause
Obsidian Therapeutics, Inc. Common Stock trading resumes
09:59 EDT Obsidian Therapeutics (OBX), Inc. Common Stock trading resumes
Obsidian announces first patient enrolled in Phase 1/2 Agni-01 study
Obsidian Therapeutics (OBX) announced the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel, an engineered TIL cel...
Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineer...
Obsidian Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Obsidian Therapeutics (OBX) with an Overweight rating and $42 price target Obsidian is a clinical stage biotech company advancing ...
Obsidian Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Obsidian Therapeutics (OBX) with an Overweight rating and $42 price target
Obsidian Therapeutics announces closing of transaction with Galera Therapeutics
Obsidian Therapeutics (OBX) announced the completion of its previously announced transaction with Galera Therapeutics (GRTX). The combined company will operate under the name Obsidian Therapeutics and...